MyMSTeam

Briumvi, also known by its drug name Ublituximab-xiiy, is a biologic immunomodulator approved by the FDA to treat adults with relapsing forms of multiple sclerosis (MS). This includes:

- Clinically isolated syndrome
- Relapsing-remitting MS
- Active secondary progressive MS

How Briumvi Works
- It is a genetically engineered Show Full Answer

Briumvi, also known by its drug name Ublituximab-xiiy, is a biologic immunomodulator approved by the FDA to treat adults with relapsing forms of multiple sclerosis (MS). This includes:

- Clinically isolated syndrome
- Relapsing-remitting MS
- Active secondary progressive MS

How Briumvi Works:
- It is a genetically engineered antibody that modulates the immune system.
- It reduces the number of CD20-positive B cells, which are involved in nerve cell attacks.

Administration:
- Briumvi is administered by intravenous infusion once every 24 weeks after initial loading doses.
- It comes as a single-use vial.

Side Effects:
- Common: Infusion reactions, upper respiratory tract infections.
- Rare but serious: Severe infusion reactions, increased risk for life-threatening or fatal infections.

For more details, you can visit the [Briumvi page on MyMSTeam](https://www.mymsteam.com/treatments/briumvi).

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Briumvi (Ublituximab-xiiy) for Multiple Sclerosis | MyMSTeam

Research Breakthroughs and Multiple Sclerosis | MyMSTeam